Cover
Cover - shares | 3 Months Ended | |
Mar. 27, 2020 | Apr. 23, 2020 | |
Entity Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 27, 2020 | |
Document Transition Report | false | |
Entity File Number | 1-37654 | |
Entity Registrant Name | Fortive Corporation | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 47-5654583 | |
Entity Address, Address Line One | 6920 Seaway Blvd | |
Entity Address, City or Town | Everett, | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98203 | |
City Area Code | 425 | |
Local Phone Number | 446-5000 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity common stock, shares outstanding | 336,856,117 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001659166 | |
Current Fiscal Year End Date | --12-31 | |
Common Stock | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | Common stock, par value $0.01 per share | |
Trading Symbol | FTV | |
Security Exchange Name | NYSE | |
Preferred Stock | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 5% Mandatory convertible preferred stock, Series A, par value $0.01 per share | |
Trading Symbol | FTV. PRA | |
Security Exchange Name | NYSE |
Consolidated Condensed Balance
Consolidated Condensed Balance Sheets - USD ($) $ in Millions | Mar. 27, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and equivalents | $ 1,040.5 | $ 1,205.2 |
Accounts receivable, net | 1,317.6 | 1,384.5 |
Inventories: | ||
Finished goods | 282.7 | 285.6 |
Work in process | 103.1 | 100.4 |
Raw materials | 264.6 | 254.3 |
Inventories | 650.4 | 640.3 |
Prepaid expenses and other current assets | 433.8 | 455.6 |
Current assets, discontinued operations | 3.3 | 3.2 |
Total current assets | 3,445.6 | 3,688.8 |
Property, plant and equipment, net of accumulated depreciation of $843.2 and $838.7 at March 27, 2020 and December 31, 2019, respectively | 520 | 519.5 |
Operating lease right-of-use assets | 200 | 206.8 |
Other assets | 744 | 779.6 |
Goodwill | 8,271.1 | 8,399.3 |
Other intangible assets, net | 3,751 | 3,845 |
Total assets | 16,931.7 | 17,439 |
Current liabilities: | ||
Current portion of long-term debt | 250 | 1,500 |
Trade accounts payable | 745.4 | 765.5 |
Current operating lease liabilities | 53.3 | 54.9 |
Accrued expenses and other current liabilities | 1,072.4 | 1,146.8 |
Total current liabilities | 2,121.1 | 3,467.2 |
Operating lease liabilities | 154.5 | 159 |
Other long-term liabilities | 1,576.7 | 1,584.2 |
Long-term debt | 5,826.1 | 4,828.4 |
Commitments and Contingencies | ||
Equity: | ||
Preferred stock: $0.01 par value, 15.0 million shares authorized; 5.0% Mandatory convertible preferred stock, series A, 1.4 million shares designated, issued and outstanding at March 27, 2020 and December 31, 2019 | 0 | 0 |
Common stock: $0.01 par value, 2.0 billion shares authorized; 337.7 and 336.9 million issued; 336.8 and 336.0 million outstanding at March 27, 2020 and December 31, 2019, respectively | 3.4 | 3.4 |
Additional paid-in capital | 3,333.7 | 3,311.1 |
Retained earnings | 4,098.6 | 4,128.8 |
Accumulated other comprehensive income (loss) | (193.6) | (56.3) |
Total Fortive stockholders’ equity | 7,242.1 | 7,387 |
Noncontrolling interests | 11.2 | 13.2 |
Total stockholders’ equity | 7,253.3 | 7,400.2 |
Total liabilities and equity | 16,931.7 | 17,439 |
Accumulated depreciation | $ 843.2 | $ 838.7 |
Consolidated Condensed Balanc_2
Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 27, 2020 | Dec. 31, 2019 | |
Statement of Financial Position [Abstract] | ||
Accumulated depreciation | $ 843.2 | $ 838.7 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 15,000,000 | 15,000,000 |
Preferred stock, dividend rate | 5.00% | 5.00% |
Preferred stock, shares issued (in shares) | 1,400,000 | 1,400,000 |
Preferred stock, shares outstanding (in shares) | 1,400,000 | 1,400,000 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 2,000,000,000 | 2,000,000,000 |
Common stock, shares issued (in shares) | 337,700,000 | 336,900,000 |
Common stock, shares outstanding (in shares) | 336,800,000 | 336,000,000 |
Consolidated Condensed Statemen
Consolidated Condensed Statements of Earnings - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Sales | $ 1,713.5 | $ 1,592.9 |
Cost of sales | (837.7) | (780.2) |
Gross profit | 875.8 | 812.7 |
Operating costs: | ||
Selling, general and administrative expenses | (557.2) | (486.4) |
Research and development expenses | (113.7) | (109) |
Impairment of goodwill | (85.3) | 0 |
Operating profit | 119.6 | 217.3 |
Non-operating expenses, net: | ||
Interest expense, net | (43.6) | (25.3) |
Other non-operating expenses, net | (4.6) | 0.4 |
Earnings from continuing operations before income taxes | 71.4 | 192.4 |
Income taxes | (29.1) | (28.4) |
Net earnings from continuing operations | 42.3 | 164 |
Earnings (loss) from discontinued operations, net of income taxes | (0.4) | 0.4 |
Net earnings | 41.9 | 164.4 |
Mandatory convertible preferred dividends | (17.3) | (17.3) |
Net earnings attributable to common stockholders | $ 24.6 | $ 147.1 |
Net earnings per common share from continuing operations: | ||
Net earnings per common share from continuing operations - basic (in dollars per share) | $ 0.07 | $ 0.44 |
Net earnings per common share from continuing operations - diluted (in dollars per share) | 0.07 | 0.43 |
Net earnings per share from discontinued operations: | ||
Net earnings per share from discontinued operations - basic (in dollars per share) | 0 | 0 |
Net earnings per share from discontinued operations - diluted (in dollars per share) | 0 | 0 |
Net earnings per share: | ||
Net earnings per share - Basic (in dollars per share) | 0.07 | 0.44 |
Net earnings per share - Diluted (in dollars per share) | $ 0.07 | $ 0.43 |
Average common stock and common equivalent shares outstanding: | ||
Weighted average common shares outstanding used in basic earnings per share (in shares) | 336.8 | 335.1 |
Weighted average common shares outstanding used in diluted earnings per share (in shares) | 340 | 339.5 |
Products | ||
Sales | $ 1,487.8 | $ 1,405.1 |
Cost of sales | (692.5) | (647.9) |
Services | ||
Sales | 225.7 | 187.8 |
Cost of sales | $ (145.2) | $ (132.3) |
Consolidated Condensed Statem_2
Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Statement of Comprehensive Income [Abstract] | ||
Net earnings | $ 41.9 | $ 164.4 |
Other comprehensive income, net of income taxes: | ||
Foreign currency translation adjustments | (136.3) | 16.7 |
Pension adjustments | (1) | 0.5 |
Total other comprehensive income (loss), net of income taxes | (137.3) | 17.2 |
Comprehensive income (loss) | $ (95.4) | $ 181.6 |
Consolidated Condensed Statem_3
Consolidated Condensed Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Preferred Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Noncontrolling Interests |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Adjusted beginning balance | $ 3.4 | $ 0 | $ 3,126 | $ 3,552.7 | $ (86.6) | $ 17.4 | |
Beginning balance (in shares) at Dec. 31, 2018 | 334.5 | 1.4 | |||||
Beginning balance at Dec. 31, 2018 | (86.6) | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings for the period | $ 164.4 | 164.4 | |||||
Dividends to common shareholders | (23.4) | (23.4) | |||||
Mandatory convertible preferred stock cumulative dividends | (17.3) | (17.3) | |||||
Other comprehensive income (loss) | 17.2 | 17.2 | |||||
Common stock-based award activity (in shares) | 0.5 | ||||||
Common stock-based award activity | 13.9 | ||||||
Issuance of 0.875% senior convertible notes due 2022 | 100.4 | ||||||
Change in noncontrolling interests | (5.4) | ||||||
Ending balance (in shares) at Mar. 29, 2019 | 335 | 1.4 | |||||
Ending balance at Mar. 29, 2019 | $ 3.4 | $ 0 | 3,240.3 | 3,676.4 | (69.4) | 12 | |
Beginning balance (in shares) at Dec. 31, 2019 | 336 | 1.4 | |||||
Beginning balance at Dec. 31, 2019 | 7,400.2 | $ 3.4 | $ 0 | 3,311.1 | 4,128.8 | (56.3) | 13.2 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings for the period | 41.9 | 41.9 | |||||
Dividends to common shareholders | (23.5) | (23.5) | |||||
Mandatory convertible preferred stock cumulative dividends | (17.3) | (17.3) | |||||
Other comprehensive income (loss) | (137.3) | (137.3) | |||||
Common stock-based award activity (in shares) | 0.8 | ||||||
Common stock-based award activity | 22.6 | ||||||
Change in noncontrolling interests | (2) | ||||||
Ending balance (in shares) at Mar. 27, 2020 | 336.8 | 1.4 | |||||
Ending balance at Mar. 27, 2020 | $ 7,253.3 | $ 3.4 | $ 0 | $ 3,333.7 | $ 4,098.6 | $ (193.6) | $ 11.2 |
Consolidated Condensed Statem_4
Consolidated Condensed Statements of Changes in Equity (Parenthetical) | Mar. 27, 2020 | Feb. 22, 2019 |
0.875% senior convertible notes due 2022 | Convertible Debt | ||
Interest rate, stated percentage | 0.875% | 0.875% |
Consolidated Condensed Statem_5
Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Cash flows from operating activities: | ||
Net earnings from continuing operations | $ 42.3 | $ 164 |
Noncash items: | ||
Depreciation | 32.1 | 29.7 |
Amortization | 85.5 | 52.2 |
Stock-based compensation expense | 16.1 | 12.9 |
Impairment of goodwill | 85.3 | 0 |
Change in trade accounts receivable, net | 22.8 | 49.9 |
Change in inventories | (16.6) | (33.3) |
Change in trade accounts payable | (6.7) | (40.6) |
Change in prepaid expenses and other assets | 30.2 | (60.4) |
Change in accrued expenses and other liabilities | (99.6) | (13.2) |
Total operating cash provided by continuing operations | 191.4 | 161.2 |
Total operating cash used in discontinued operations | (0.4) | (5) |
Net cash provided by operating activities | 191 | 156.2 |
Cash flows from investing activities: | ||
Payments for additions to property, plant and equipment | (33.8) | (24) |
Cash paid for acquisitions, net of cash received | (10.6) | 0 |
All other investing activities | 0.2 | 0 |
Net cash used in investing activities | (44.2) | (24) |
Cash flows from financing activities: | ||
Net proceeds from (repayments of) commercial paper borrowings | (382.8) | 443.8 |
Proceeds from borrowings (maturities longer than 90 days), net of issuance costs of $1 million and $24 million in 2020 and 2019, respectively | 373.8 | 2,417.8 |
Repayment of borrowings (maturities greater than 90 days) | (250) | (402.9) |
Payment of common stock cash dividend to shareholders | (23.5) | (23.4) |
Payment of mandatory convertible preferred stock cash dividend to shareholders | 0 | (17.3) |
All other financing activities | (0.7) | (6.8) |
Net cash (used in) provided by financing activities | (283.2) | 2,411.2 |
Effect of exchange rate changes on cash and equivalents | (28.3) | 7.1 |
Net change in cash and equivalents | (164.7) | 2,550.5 |
Beginning balance of cash and equivalents | 1,205.2 | 1,178.4 |
Ending balance of cash and equivalents | $ 1,040.5 | $ 3,728.9 |
Consolidated Condensed Statem_6
Consolidated Condensed Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Statement of Cash Flows [Abstract] | ||
Payments of debt issuance costs | $ 1 | $ 24 |
Business Overview
Business Overview | 3 Months Ended |
Mar. 27, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Overview | NOTE 1. BUSINESS OVERVIEW Fortive Corporation (“Fortive,” the “Company,” “we,” “us,” or “our”) is a diversified industrial technology growth company encompassing businesses that are recognized leaders in attractive markets. Our well-known brands hold leading positions in field solutions, product realization, sensing technologies, health, transportation technologies, and franchise distribution. Our businesses design, develop, service, manufacture, and market professional and engineered products, software, and services for a variety of end markets, building upon leading brand names, innovative technology, and significant market positions. We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2019 and the footnotes (“Notes”) thereto included within our 2019 Annual Report on Form 10-K. In our opinion, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to fairly present our financial position as of March 27, 2020 and December 31, 2019, our results of operations for the three months ended March 27, 2020 and March 29, 2019, and cash flows for the three months ended March 27, 2020 and March 29, 2019. Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Reclassification of certain prior year amounts have been made to conform to current year presentation. On September 4, 2019, we announced our intention to separate into two independent, publicly traded companies, subject to the satisfaction of certain conditions. The separation will create (i) an industrial technology company, retaining the Fortive name, with a differentiated portfolio of growth-oriented businesses focused on connected workflow solutions that incorporate advanced sensors, instrumentation, software, data, and analytics, and (ii) a global industrial company (“Vontier”) consisting of our Transportation Technologies and Franchise Distribution platforms with a focus on growth opportunities in the rapidly evolving transportation and mobility markets. The proposed separation is expected to be structured in a tax-efficient manner. The timing and structure of the separation will depend, in part, on the state of the capital market environment over time as affected by the future evolution of the COVID-19 pandemic and its impact on the global economy. All assets, liabilities, revenues, and expenses of the businesses comprising Vontier are included in continuing operations in the accompanying consolidated condensed financial statements. On October 1, 2018, we completed the split-off of businesses in our automation and specialty platform (the “A&S Business”) and have reported the A&S Business as discontinued operations in our Consolidated Condensed Statements of Earnings, Consolidated Condensed Balance Sheets, and Consolidated Condensed Statements of Cash Flows for all periods presented. The impact of discontinued operations in our consolidated condensed financial statements was immaterial for both periods presented, and therefore, discussion within these notes to the consolidated condensed financial statements relates to continuing operations. Accumulated Other Comprehensive Income (Loss) —Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. We have designated our Euro-denominated commercial paper and ¥13.8 billion senior unsecured term facility loan as net investment hedges of our investment in certain foreign operations. Accordingly, foreign currency transaction gains or losses on the debt are deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. We recognized gains of $0.9 million and $7.2 million for the three months ended March 27, 2020 and March 29, 2019, respectively, in other comprehensive income related to the net investment hedges. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three-month periods ended March 27, 2020 and March 29, 2019. The changes in AOCI by component are summarized below ($ in millions): Foreign Pension adjustments (b) Total For the Three Months Ended March 27, 2020: Balance, December 31, 2019 $ 21.2 $ (77.5) $ (56.3) Other comprehensive income (loss) before reclassifications, net of income taxes (136.3) — (136.3) Amounts reclassified from accumulated other comprehensive income (loss): Decrease — (1.2) (a) (1.2) Income tax impact — 0.2 0.2 Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — (1.0) (1.0) Net current period other comprehensive income (loss), net of income taxes (136.3) (1.0) (137.3) Balance, March 27, 2020 $ (115.1) $ (78.5) $ (193.6) For the Three Months Ended March 29, 2019: Balance, December 31, 2018 $ (29.3) $ (57.3) $ (86.6) Other comprehensive income (loss) before reclassifications, net of income taxes 16.7 — 16.7 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 0.7 (a) 0.7 Income tax impact — (0.2) (0.2) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.5 0.5 Net current period other comprehensive income (loss), net of income taxes 16.7 0.5 17.2 Balance, March 29, 2019 $ (12.6) $ (56.8) $ (69.4) (a) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 7 for additional details). (b) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans. Recently Adopted Accounting Standard —In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach, based on expected losses, to estimate credit losses on certain types of financial instruments, including financing, trade accounts, and unbilled receivables. On January 1, 2020, we adopted ASU 2016-13 and recognized in our Consolidated Condensed Balance Sheet as of January 1, 2020 an increase in the allowance for trade accounts, unbilled, and fi nancing receivables of $40.0 million, with a corresponding net of tax adjustment to beginning retained earnings of $31.3 million. Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Prior to the adoption of ASU 2016-13 on January 1, 2020, we recognized an allowance for incurred losses when they were probable based on many quantitative and qualitative factors, including delinquency. After the adoption of ASU 2016-13, we measure our allowance to reflect expected credit losses over the remaining contractual life of the asset. We pool assets with similar risk characteristics for this measurement based on attributes that may include asset type, duration, and/or credit risk rating. The future expected losses of each pool are estimated based on numerous quantitative and qualitative factors reflecting management’s estimate of collectibility over the remaining contractual life of the pooled assets, including: • duration; • historical, current, and forecasted future loss experience by asset type; • historical, current, and forecasted delinquency and write-off trends; • historical, current, and forecasted economic conditions; and • historical, current, and forecasted credit risk. Expected credit losses of the assets originated during the quarter ended March 27, 2020, as well as changes to expected losses during the same period, are recognized in earnings for the period ended March 27, 2020. As a result of the adoption of ASU 2016-13, we have updated our significant accounting policy related to unbilled, trade accounts, and financing receivables and allowances for credit losses as of March 27, 2020 from what was previously disclosed in our audited financial statements for the year ended December 31, 2019 as follows: All trade accounts, financing, and unbilled receivables are reported in the accompanying Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled, trade accounts, and financing receivable portfolios over the life of the underlying assets. Determination of the allowances requires management to exercise judgment about the severity of credit losses, which includes judgments regarding the risk profile of each underlying receivable and expectations regarding the impact of current and future economic conditions on the creditworthiness of its customers. We regularly perform detailed reviews of our portfolios to evaluate the collectability of receivables based on a combination of past, current, and future financial and qualitative factors that may affect customers’ ability to pay, including customers’ financial condition, collateral, debt-servicing ability, payment experience, credit bureau information, and economic conditions. In circumstances where we are aware of a specific customer’s inability to meet its financial obligations, a specific reserve is recorded against amounts due to reduce the recognized receivable to the amount reasonably expected to be collected. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. Recent deterioration in overall global economic conditions and worldwide capital markets as a result of the COVID-19 pandemic may negatively impact our customers’ ability to pay and, as a result, may increase the difficulty in collecting trade accounts, financing, and unbilled receivables. We did not realize notable increases in loss rates and delinquencies during the first quarter ended March 27, 2020, and given the nature of our portfolio of receivables, our historical experience during times of challenging economic conditions, and our forecasted future impact of COVID-19 on our customer’s ability to pay, we did not record material provisions for credit losses as a result of the COVID-19 pandemic during the first quarter ended March 27, 2020. If the financial condition of our customers were to deteriorate beyond our current estimates, resulting in an impairment of their ability to make payments, we would be required to write-off additional receivable balances, which would adversely impact our net earnings and financial condition. The following is a rollforward of the aggregated allowance for credit losses related to our trade accounts, unbilled, and financing receivables as of March 27, 2020 ($ in millions): Balance, December 31, 2019 $ 82.1 Transition Adjustment 40.0 Provision 12.0 Write-offs (13.2) FX and Other (5.1) Balance, March 27, 2020 $ 115.8 |
Acquisitions
Acquisitions | 3 Months Ended |
Mar. 27, 2020 | |
Business Combinations [Abstract] | |
Acquisitions | NOTE 2. ACQUISITIONS For a description of our material acquisition activity refer to Note 3 of our 2019 Annual Report on Form 10-K. We continually evaluate potential mergers, acquisitions, and divestitures that align with our strategy and expedite the evolution of our portfolio of businesses into new and attractive areas. We have completed a number of acquisitions that have been accounted for as purchases and resulted in the recognition of goodwill in our financial statements. This goodwill arises because the purchase price for each acquired business reflects a number of factors including the complimentary fit, acceleration of our strategy and synergies the business brings with respect to our existing operations, the future earnings and cash flow potential of the business, the potential to add other strategically complimentary acquisitions to the acquired business, the scarce or unique nature of the business in its markets, competition to acquire the business, the valuation of similar businesses in the marketplace (as reflected in a multiple of revenues, earnings or cash flows), and the avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance our existing offerings to key target markets and develop new and profitable businesses. We make an initial allocation of the purchase price at the date of acquisition based on our understanding of the fair value of the acquired assets and assumed liabilities. We obtain this information during due diligence and through other sources. In the months after closing, as we obtain additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learn more about the newly acquired business, we are able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. We are in the process of obtaining valuations of certain acquired assets and evaluating the tax impact of certain acquisitions. We make appropriate adjustments to purchase price allocations prior to completion of the applicable measurement period, as required. During the three months ended March 27, 2020, we recorded adjustments to the preliminary purchase price allocation of acquisitions that closed during 2019 that resulted in a net increase to goodwill of $13.2 million, prior to foreign currency translation impacts. Advanced Sterilization Products On April 1, 2019 (the “Principal Closing Date”), we acquired the advanced sterilization products business (“ASP”) of Johnson & Johnson, a New Jersey corporation (“Johnson & Johnson”) for an aggregate purchase price of $2.7 billion (the “Transaction”), subject to certain post-closing adjustments set forth in a Stock and Asset Purchase Agreement, dated effective as of June 6, 2018 (the “Purchase Agreement”), between the Company and Ethicon, Inc., a New Jersey corporation (“Ethicon”) and a wholly owned subsidiary of Johnson & Johnson. ASP engages in the research, development, manufacture, marketing, distribution, and sale of low-temperature terminal sterilization and high-level disinfection products. ASP generated annual revenues of approximately $800 million in 2018. On the Principal Closing Date, we paid $2.7 billion in cash and obtained the transferred assets and assumed liabilities in 20 countries (“Principal Countries”), general patent and trademark assignments, and all transferred equity interests in ASP. ASP has operations in an additional 39 countries (“Non-Principal Countries”). The transferred assets and liabilities associated with these operations will close when requirements of country-specific agreements or regulatory approvals are satisfied. The $2.7 billion purchase price was paid in exchange for ASP’s businesses in both Principal and Non-Principal Countries. As of March 27, 2020, we have closed 20 Principal Countries and six Non-Principal Countries that, in aggregate, accounted for approximately 99% of the preliminary valuation of ASP. The remaining Non-Principal Countries represent approximately 1% of the preliminary valuation of ASP, or $31.1 million , which is included as a prepaid asset in Other assets in the Condensed Consolidated Balance Sheet. As each Non-Principal Country closes, we reduce the prepaid asset and record the fair value of the assets acquired and liabilities assumed. All of the provisional goodwill associated with the Transaction is included in goodwill at March 27, 2020, and the majority of the provisional goodwill is tax deductible. In addition, the Company entered into a transition services agreement with Johnson & Johnson for certain administrative and operational services, and distribution agreements in the Non-Principal Countries. Under the distribution agreements, ASP sells finished goods to Ethicon at prices agreed by the parties. ASP recognizes these sales as revenue when the conditions for revenue recognition are met. Following the sale of finished goods by ASP, Ethicon obtains title of the finished goods, has full authority to sell and market the finished goods to end customers as it sees fit, and retains any revenue and profit from sale. As of March 27, 2020, no further services are being provided under the transition services agreement in the U.S., Canada, Mexico, Australia, and New Zealand. The following table summarizes the provisional fair value estimates of the assets acquired and liabilities assumed of Principal and Non-Principal Countries that have been transferred to ASP as of March 27, 2020, prior to foreign currency impacts; we did not acquire accounts receivable or accounts payable from Johnson & Johnson: Advanced Sterilization Products Inventories $ 176.4 Property, plant and equipment 47.5 Goodwill 1,437.2 Other intangible assets, primarily customer relationships, trade names and technology 1,123.5 Other assets and liabilities, net (79.7) Total consideration allocated to Principal Countries and closed Non-Principal Countries 2,704.9 Prepaid acquisition asset related to remaining Non-Principal Countries 31.1 Net cash consideration $ 2,736.0 Revenue and operating loss attributable to ASP for the three months ended March 27, 2020 were $159 million and $26 million, respectively, and are included in our Professional Instrumentation segment. Operating loss includes a combined $52 million of amor tization of intangible assets, acquisition-related fair value adjustments, and post-close transaction and integration costs associated with the Transaction of for the three months ended March 27, 2020. Post-close transaction and integration costs associated with the Transaction were approximately $20 million and are recorded in selling, general, and administrative expenses for the three months ended March 27, 2020, and were primarily amounts paid to third-party advisers. |
Goodwill
Goodwill | 3 Months Ended |
Mar. 27, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | NOTE 3. GOODWILL The following is a rollforward of our carrying value of goodwill by segment ($ in millions): Professional Instrumentation (a) Industrial Technologies (a) Total Goodwill Balance, December 31, 2019 $ 7,242.6 $ 1,156.7 $ 8,399.3 Acquisitions 13.2 — 13.2 Impairment charge — (85.3) (85.3) Foreign currency translation and other (26.9) (29.2) (56.1) Balance, March 27, 2020 $ 7,228.9 $ 1,042.2 $ 8,271.1 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. We test goodwill for impairment annually in the fourth quarter of each year and may review goodwill in interim periods if certain events occur or circumstances change. Based on our most annual impairment assessment, we concluded that the goodwill for our twelve reporting units was not impaired as of December 31, 2019. The results of our fourth quarter 2019 goodwill impairment testing indicated the excess of the estimated fair value over the carrying value (expressed as a percentage of carrying value) of our Telematics reporting unit was approximately 5%, and as such, management continued to monitor the performance of Telematics during the first quarter of 2020. In connection with management’s updated forecast for the Telematics reporting unit that indicated a decline in sales and operating profit to levels lower than previously forecasted, due in large part to the impacts of the COVID-19 pandemic, we performed a quantitative impairment assessment over the Telematics reporting unit on March 27, 2020. We estimated the fair value of the Telematics reporting unit by considering an income approach, using the discounted cash flow method. The income approach was based on projected future (debt-free) cash flows that were discounted to present value and assumed a terminal growth value. The discount rate was based on the reporting unit’s weighted average cost of capital, taking into account market participant assumptions. Management’s revenue and profitability forecasts used in the valuation considered recent and historical performance of the reporting unit, strategic initiatives, industry trends, and the current and future expectations of the macroeconomic environment. Assumptions used in the valuation were similar to those that would be used by market participants performing independent valuations of this reporting unit. Key assumptions developed by management and used in the quantitative analysis included the following: • Near-term revenue declines in 2020 with later-term improvements over the projection period; • Improved profitability over the projection period, trending consistent with revenues; and • Market-based discount rates. We did not consider the market approach in our fair value calculation given the near term uncertainty in the market data and forecasts of the guideline companies upon which the approach relies. As a result of the interim impairment testing performed, we concluded that the estimated fair value of our Telematics reporting unit was less than our carrying value as of March 27, 2020, and recorded a non-cash goodwill impairment charge of $85.3 million during the three months ended March 27, 2020 to reduce the carrying value of goodwill to $235.9 million. The charge is included in the operating results of our Industrial Technologies segment. The impairment testing of goodwill utilized significant unobservable inputs (Level 3 in the fair value hierarchy) to determine the estimated fair value. The factors used in our impairment analysis are inherently subject to uncertainty, particularly in light of the recent deterioration in overall global economic conditions and capital markets due to COVID-19. While we believe we made reasonable estimates and assumptions to calculate the fair value of the Telematics reporting unit, alternative interpretations of the qualitative inputs considered may have resulted in different conclusions regarding the size of the impairment, and it is possible our conclusions could change in future periods. The results of our 2019 impairment testing indicated our eleven other reporting units had fair values that were significantly in excess of their carrying values. We evaluated the impact of the deterioration in overall global economic conditions as a result of the COVID-19 pandemic, including the change in our market capitalization and changes in forecasts for each reporting unit, and determined no triggering events had occurred. There can be no assurance the estimates and assumptions used in our goodwill impairment testing performed in the first quarter of 2020 will prove to be accurate predictions of the future. Specifically, variations in our assumptions related to business performance and execution of planned growth strategies and the discount rate could impact future conclusions. A future impairment charge for goodwill could have a material effect on our consolidated financial position and results of operations. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 27, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | NOTE 4. FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. • Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions): Quoted Prices Significant Other Significant Total March 27, 2020 Deferred compensation liabilities $ — $ 27.3 $ — $ 27.3 December 31, 2019 Deferred compensation liabilities $ — $ 29.6 $ — $ 29.6 Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are presented as a component of our compensation and benefits accrual included in Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates. Nonrecurring Fair Value Measurements Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets. On March 27, 2020, we evaluated our Telematics reporting unit for impairment and recorded an impairment of goodwill of $85.3 million to adjust the carrying value of the reporting unit to the estimated fair value. Refer to Note 3 for additional information regarding the inputs and methodology used to estimate the fair value. We evaluated our other non-financial assets as of March 27, 2020 and determined no impairment was necessary. Fair Value of Financial Instruments The carrying amount and fair value of financial instruments are as follows ($ in millions): March 27, 2020 December 31, 2019 Carrying Amount Fair Value Carrying Amount Fair Value Current portion of long-term debt $ 250.0 $ 250.0 $ 1,500.0 $ 1,500.0 Long-term debt, net of current maturities $ 5,826.1 $ 5,755.9 $ 4,828.4 $ 4,992.3 As of March 27, 2020 and December 31, 2019, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1. The fair values of the current portion of long-term debt and long-term debt were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the incurrence of the borrowing. The fair value of cash and cash equivalents, accounts receivable, net and trade accounts payable approximates their carrying amount due to the short-term maturities of these instruments. |
Financing and Capital
Financing and Capital | 3 Months Ended |
Mar. 27, 2020 | |
Debt Disclosure [Abstract] | |
Financing and Capital | NOTE 5. FINANCING AND CAPITAL The carrying value of the components of our long-term debt were as follows ($ in millions): March 27, 2020 December 31, 2019 U.S. dollar-denominated commercial paper $ 501.2 $ 884.4 Euro-denominated commercial paper 262.4 264.1 Delayed-draw term loan due 2020 1,000.0 1,000.0 Term Loan due 2020 250.0 500.0 Term Loan due 2021 373.9 — Yen variable interest rate term loan due 2022 127.8 127.1 2.35% senior unsecured notes due 2021 748.6 748.2 3.15% senior unsecured notes due 2026 893.3 893.0 4.30% senior unsecured notes due 2046 547.0 547.0 0.875% senior convertible notes due 2022 1,357.7 1,347.3 Other 14.2 17.3 Long-term debt 6,076.1 6,328.4 Less: current portion of long-term debt 250.0 1,500.0 Long-term debt, net of current maturities $ 5,826.1 $ 4,828.4 Aggregate unamortized debt discounts, premiums and issuance costs of $93 million and $102 million as of March 27, 2020 and December 31, 2019, respectively, are netted against the principal amounts of the components of debt in the table above. Refer to Note 10 of our 2019 Annual Report on Form 10-K for further details of our debt financing. We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Due to recent volatility and disruption in the commercial paper market, we have temporarily reduced our reliance on this source of funding, and consequently refinanced approximately $365 million and $420 million of our outstanding commercial paper during the three months ended March 27, 2020 and in April 2020, respectively, largely with a 364 day delayed-draw term loan, as detailed in the 2021 Term Loan section below. Credit support for the Commercial Paper Programs is provided by a five Our credit facility agreements require, among others, that we maintain certain financial covenants and we were in compliance with all of our financial covenants on March 27, 2020. In addition, on April 24, 2020, we amended (the “Amendments”) the credit agreement for each of our (i) $500 million delayed draw term loan facility, with $250 million in principal amount outstanding as of March 27, 2020 (“2020 Term Loan”), (ii) $1.0 billion delayed draw term loan facility, with $1.0 billion in principal amount outstanding as of March 27, 2020 (the “2020 Delayed-Draw Term Loan”), (iii) $750 million delayed draw term loan facility, with $375 million in principal amount outstanding as of March 27, 2020 (“2021 Term Loan”), and (iv) $2.0 billion Revolving Credit Facility, with no borrowings thereunder as of March 27, 2020 as follows: • For any four fiscal quarters ending in the periods noted below (each an “Adjusted Four Quarters”) that end prior to the maturity date of the applicable facility, the maximum permitted consolidated net leverage ratio of consolidated net funded indebtedness to consolidated EBITDA was increased from 3.50 to 1.00 to, (i) with respect to the four fiscal quarters ending June 26, 2020, September 25, 2020, December 31, 2020, or April 2, 2021, 4.75 to 1.00, (ii) with respect to the four fiscal quarters ending July 2, 2021, 4.5 to 1.0, (iii) with respect to the four fiscal quarters ending October 1, 2021, 4.25 to 1.0 and (iv) with respect to the four fiscal quarters ending December 31, 2021, 3.75 to 1.0; provided however, that for any four fiscal quarters that are not an Adjusted Four Quarters, the maximum permitted consolidated net leverage ratio remains at 3.5 to 1.0, as may be increased to 4.0 to 1.0 following a material acquisition (the “Unadjusted Maximum Ratio”). • The maturity date for the 2020 Delayed-Draw Term Loan was extended from August 28, 2020 to May 30, 2021. • From April 24, 2020 to December 31, 2021, the minimum London inter-bank offered rate (“LIBOR”) for each of the facilities will increase from 0% to 0.25%, and the minimum base rate for each of the facilities will increase from 1.00% to 1.25%. In addition, with respect to the Revolving Credit Facility and for any Adjusted Four Quarters in which the consolidated net leverage ratio is greater than the Unadjusted Maximum Ratio, the applicable margin (as determined based on our long-term debt credit rating) for any LIBOR rate loans will increase from a range of 80.5 and 117.5 basis points to a range of 118.0 and 155.0 basis points and for any base rate loans from a range of 0.0 and 17.5 basis points to a range of 18.0 and 55.0 basis points. Furthermore, with respect to the 2020 Delayed-Draw Term Loan, the applicable margin (as determined based on our long-term debt credit rating) for any LIBOR rate loans will increase from a range of 75.0 and 97.5 basis points to a range of 155.0 and 180.0 basis points and for any base rate loans from 0.0 to a range of 55.0 and 80.0 basis points. • From April 24, 2020 to December 31, 2021, the maximum principal amount of secured indebtedness, other than certain types of secured indebtedness expressly permitted under each credit agreement, is decreased from 15% of our consolidated net assets (when added together with indebtedness incurred or guaranteed by any of our subsidiaries) to 11.25% of our consolidated net assets (when added together with indebtedness incurred or guaranteed by any of our subsidiaries). In connection with the Amendments, we incurred approximately $6.5 million of fees. Convertible Senior Notes On February 22, 2019, we issued $1.4 billion in aggregate principal amount of our 0.875% Convertible Senior Notes due 2022 (the “Convertible Notes”), including $187.5 million in aggregate principal amount resulting from an exercise in full of an over-allotment option. The Convertible Notes were issued in a private placement to certain initial purchasers for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The Convertible Notes bear interest at a rate of 0.875% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2019. The Convertible Notes mature on February 15, 2022, unless earlier repurchased or converted in accordance with their terms prior to such date. The Convertible Notes are convertible into shares of our common stock at an initial conversion rate of 9.3777 shares per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of $106.64 per share), subject to adjustment upon the occurrence of certain events. The initial conversion price represents a premium of approximately 32.5% to the $80.48 per share closing price of our common stock on February 19, 2019. Upon conversion of the Convertible Notes, holders will receive cash, shares of our common stock, or a combination thereof, at Fortive’s election. Our current intention is to settle such conversions through cash up to the principal amount of the converted Convertible Notes and through shares of our common stock for conversion value, if any, in excess of the principal amount of the converted Convertible Notes. Of the $1.4 billion in principal amount from the issuance of the Convertible Notes, $1.3 billion was classified as debt and $102.2 million was classified as equity, using an assumed effective interest rate of 3.38%. Debt issuance costs of $24.3 million were proportionately allocated to debt and equity. We recognized $13.4 million in interest expense during the three months ended March 27, 2020, of which $3.1 million related to the contractual coupon rate of 0.875% and $1.9 million was attributable to the amortization of debt issuance costs. The discount at issuance was $102.2 million and is being amortized over a three Prior to November 15, 2021, the Convertible Notes will be convertible only upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the business day immediately preceding the maturity date of the Convertible Notes. 2020 Term Loan On October 25, 2019, we entered into a credit facility agreement that provides for the 2020 Term Loan in an aggregate principal amount of $300 million. On October 25, 2019, we drew down the full $300 million available under the 2020 Term Loan in order to fund, in part, the Censis acquisition. We subsequently increased the size of this facility by $200 million on November 8, 2019 and drew the additional amount on the same day resulting in an outstanding amount of $500 million. The 2020 Term Loan bears interest at a variable rate equal to LIBOR plus a ratings-based margin currently at 75 basis points. As of March 27, 2020, borrowings under this facility bore an interest rate of 1.55% per annum. The 2020 Term Loan is due on October 23, 2020 and prepayable at our option. We are not permitted to re-borrow once the term loan is repaid. The terms and conditions, including covenants, applicable to the 2020 Term Loan are substantially similar to those applicable to our Revolving Credit Facility. On February 26, 2020, we prepaid $250 million of the 2020 Term Loan. The prepayment fees associated with this payment were immaterial. 2020 Delayed-Draw Term Loan On March 1, 2019, we entered into a credit facility agreement that provides for the 2020 Delayed-Draw Term Loan in an aggregate principal amount of $1.0 billion. On March 20, 2019, we drew down the full $1.0 billion available under the 2020 Delayed-Draw Term Loan in order to fund, in part, the ASP acquisition. The 2020 Delayed-Draw Term Loan bears interest at a variable rate equal to LIBOR plus a ratings based margin, prior to the Amendments, at 75 basis points and, following the Amendments, at 155 basis points. As of March 27, 2020 and prior to the Amendments noted above, borrowings under this facility bore an interest rate of 1.52% per annum. The 2020 Delayed-Draw Term Loan is prepayable at our option, and we are not permitted to re-borrow once the term loan is repaid. The terms and conditions, including covenants, applicable to the 2020 Delayed-Draw Term Loan are substantially similar to those applicable to our Revolving Credit Facility. On February 25, 2020, we extended the maturity of the 2020 Delayed-Draw Term Loan to August 28, 2020. Additionally, on April 24, 2020 we further extended the maturity to May 30, 2021 and therefore, have classified the outstanding amount as long-term debt in our Consolidated Condensed Balance Sheet as of March 27, 2020. We were in compliance with our covenants both before and after the extension. The 2020 Delayed-Draw Term Loan is not callable and remains prepayable at our option. 2021 Te rm Loan On March 23, 2020, we entered into a credit facility agreement that provides for the 2021 Term Loan in an aggregate principal amount of $425 million. On the same day, we drew down $375 million available under the 2021 Term Loan. We subsequently increased the size of this facility by $325 million on April 3, 2020, and drew the additional $375 million in April 2020, resulting in an outstanding amount of $750 million. We paid approximately $2.0 million in debt issuance costs associated with the 2021 Term Loan. The borrowings from this credit facility were used for settlement of outstanding commercial paper other than as described below. The 2021 Term Loan bears interest at a variable rate equal to LIBOR plus a ratings-based margin currently at 155 basis points. As of March 27, 2020, borrowings under this facility bore an interest rate of 2.51% per annum. The 2021 Term Loan is due on March 19, 2021 and prepayable at our option. We are not permitted to re-borrow once the term loan is repaid. The terms and conditions, including covenants, applicable to the 2021 Term Loan, are substantially similar to those applicable to our Revolving Credit Facility. We classified our borrowings outstanding under the 2021 Term Loan as long-term debt in the accompanying Consolidated Condensed Balance Sheet as of March 27, 2020, as we have the intent and ability, as supported by availability under the Revolving Credit Facility, to refinance these borrowings for at least one year from the balance sheet date. As our short-term credit facilities and commercial paper obligations mature, we may issue additional short-term commercial paper and other short-term debt to refinance all or part of these borrowings. Commercial Paper The details of our Commercial Paper Programs as of March 27, 2020 are as follows ($ in millions): Carrying value Annual effective rate Weighted average remaining maturity (in days) U.S. dollar-denominated commercial paper $ 501.2 2.67 % 37 Euro-denominated commercial paper $ 262.4 (0.11) % 34 |
Sales
Sales | 3 Months Ended |
Mar. 27, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Sales | NOTE 6. SALES We derive revenues primarily from the sale of Professional Instrumentation and Industrial Technologies products and software and services. Revenue is recognized when control of promised products and software or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products and software or services. Sales of products and software includes revenues from the sale of products and equipment, software as a service product offerings, and equipment rentals. Sales of services includes revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, and services related to previously sold products. Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $76 million as of March 27, 2020 and $79 million as of December 31, 2019. Contract Costs — We incur direct incremental costs to obtain certain contracts, typically sales-related commissions and costs associated with assets used by our customers in certain service arrangements. Deferred sales-related commissions are generally not capitalized as the amortization period is one year or less, and we elected to use the practical expedient to expense these sales commissions as incurred. As of March 27, 2020 and December 31, 2019, we had $119 million and $147 million, respectively, in net revenue-related contract assets primarily related to certain software contracts. Revenue-related contract assets are recorded in the Prepaid expenses and other current assets and Other assets line items in our Condensed Consolidated Balance Sheets. These assets have estimated useful lives between 3 and 8 years. Impairment losses recognized on our revenue-related contract assets were immaterial during the three months ended March 27, 2020. Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to PCS and extended warranty sales, where in most cases we receive up-front payment and recognize revenue over the support term. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Our contract liabilities consisted of the following ($ in millions): March 27, 2020 December 31, 2019 Deferred revenue - current $ 423.5 $ 410.1 Deferred revenue - noncurrent 95.1 99.2 Total contract liabilities $ 518.6 $ 509.3 During the three months ended March 27, 2020, we recognized $126 million of revenue related to our contract liabilities at December 31, 2019. The change in our contract liabilities from December 31, 2019 to March 27, 2020 was primarily due to the timing of cash receipts and sales of PCS and extended warranty services. Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, noncancelable orders, with expected delivery dates to customers greater than one year from March 27, 2020, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below. The aggregate performance obligations attributable to each of our segments is as follows ($ in millions): March 27, 2020 Professional Instrumentation $ 145.2 Industrial Technologies 379.4 Total remaining performance obligations $ 524.6 The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 40 percent within the next two years, approximately 70 percent within the next three years and substantially all within four years. Disaggregation of Revenue We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, major product group and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Disaggregation of revenue for the three months ended March 27, 2020 is presented as follows ($ in millions): Total Professional Instrumentation Industrial Technologies Sales: Sales of products and software $ 1,487.8 $ 940.5 $ 547.3 Sales of services 225.7 163.9 61.8 Total $ 1,713.5 $ 1,104.4 $ 609.1 Geographic: United States $ 1,019.8 $ 594.9 $ 424.9 China 127.5 119.0 8.5 All other (each country individually less than 5% of total sales) 566.2 390.5 175.7 Total $ 1,713.5 $ 1,104.4 $ 609.1 Major Products Group: Professional tools and equipment $ 1,107.3 $ 658.6 $ 448.7 Industrial automation, controls and sensors 109.6 109.6 — Franchise distribution 160.4 — 160.4 Medical technologies 280.0 280.0 — All other 56.2 56.2 — Total $ 1,713.5 $ 1,104.4 $ 609.1 End markets: Direct sales: Retail fueling (a) $ 396.5 $ — $ 396.5 Industrial & Manufacturing 109.0 109.0 — Vehicle repair (a) 143.2 — 143.2 Utilities & Power 43.9 43.9 — Medical (a) 280.0 280.0 — Other 355.8 290.8 65.0 Total direct sales 1,328.4 723.7 604.7 Distributors (a) 385.1 380.7 4.4 Total $ 1,713.5 $ 1,104.4 $ 609.1 (a) Retail fueling, vehicle repair and medical include sales to these end markets made through third-party distributors. Total distributor sales for the three months ended March 27, 2020 was $739.0 million. Disaggregation of revenue for the three months ended March 29, 2019 is presented as follows ($ in millions): Total Professional Instrumentation (a) Industrial Technologies (a) Sales: Sales of products and software $ 1,405.1 $ 856.2 $ 548.9 Sales of services 187.8 121.5 66.3 Total $ 1,592.9 $ 977.7 $ 615.2 Geographic: United States $ 887.6 $ 496.1 $ 391.5 China 150.0 131.2 18.8 All other (each country individually less than 5% of total sales) 555.3 350.4 204.9 Total $ 1,592.9 $ 977.7 $ 615.2 Major Products Group: Professional tools and equipment $ 1,151.8 $ 705.6 $ 446.2 Industrial automation, controls and sensors 120.1 120.1 — Franchise distribution 169.0 — 169.0 Medical technologies (d) 99.0 99.0 — All other 53.0 53.0 — Total $ 1,592.9 $ 977.7 $ 615.2 End markets: Direct sales: Retail fueling (c) $ 388.2 $ — $ 388.2 Industrial & Manufacturing 109.6 109.6 — Vehicle repair (c) 153.8 — 153.8 Utilities & Power 49.6 49.6 — Medical (c) (b) 99.0 99.0 — Other 377.7 309.9 67.8 Total direct sales 1,177.9 568.1 609.8 Distributors (c) 415.0 409.6 5.4 Total $ 1,592.9 $ 977.7 $ 615.2 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. (b) Sales were previously disclosed in Other. (c) Retail fueling, vehicle repair and medical include sales to these end markets made through third-party distributors. Total distributor sales for the three months ended March 29, 2019 was $745.2 million. (d) Sales were previously disclosed in Professional tools and equipment, Industrial automation, controls and sensors, and All other. |
Pension Plans
Pension Plans | 3 Months Ended |
Mar. 27, 2020 | |
Retirement Benefits [Abstract] | |
Pension Plans | NOTE 7. PENSION PLANS For a full description of our noncontributory defined benefit pension plans refer to Note 12 of our 2019 Annual Report on Form 10-K. The following sets forth the components of our net periodic costs associated with our noncontributory defined benefit pension plans ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 U.S. Pension Benefits: Interest cost $ 0.3 $ 0.4 Expected return on plan assets (0.3) (0.3) Amortization of net loss 0.1 — Net periodic pension cost $ 0.1 $ 0.1 Non-U.S. Pension Benefits: Service cost $ 1.1 $ 0.3 Interest cost 1.0 1.4 Expected return on plan assets (1.4) (1.4) Amortization of net loss 1.1 0.7 Amortization of prior service cost 0.1 — Net periodic pension cost $ 1.9 $ 1.0 We report all components of net periodic pension costs, with the exception of service costs, in other non-operating expenses as a component of non-operating income in the accompanying Consolidated Condensed Statements of Earnings. Service costs are reported in cost of sales and selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings according to the classification of the participant’s compensation. Employer Contributions During 2020, our cash contribution requirements for our non-U.S. and U.S. defined benefit plans are expected to be approximately $10.7 million and $0.8 million, respectively. The actual amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors. In response to the COVID-19 pandemic, certain countries have enacted or proposed legislation to enable employers to defer minimum contributions to qualified defined benefit plans during all or part of 2020. We are actively assessing the available reliefs and will continue to monitor and utilize relevant legislative reliefs as we deem prudent. This may reduce our cash contribution requirements under our defined benefit plans in 2020. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 27, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE 8. INCOME TAXES Our effective tax rate for the three months ended March 27, 2020 was 40.8% as compared to 14.8% for the three months ended March 29, 2019. The year-over-year increase was due primarily to a non-deductible goodwill impairment and tax costs associated with repatriating a portion of our previously reinvested earnings outside of the United States. These factors were partially offset by favorable impacts of a higher mix of income in jurisdictions with lower tax rates than the U.S. federal statutory rate of 21% and increases in favorable impacts of certain federal and international tax benefits. Our effective tax rate for 2020 and 2019 differs from the U.S. federal statutory rate of 21% due primarily to the positive and negative effects of the Tax Cuts and Jobs Act (“TCJA”), U.S. federal permanent differences, the impact of credits and deductions provided by law, and current year earnings outside the United States that are indefinitely reinvested and taxed at rates lower than the U.S. federal statutory rate. Specific to 2020, our effective tax rate also differs from the U.S. federal statutory rate of 21% due to a non-deductible goodwill impairment and the tax costs associated with repatriating a portion of our previously reinvested earnings outside of the United States. |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 27, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | NOTE 9. STOCK-BASED COMPENSATION Our stock-based compensation program (the “Stock Plan”) provides for the grant of stock appreciation rights, performance stock units, restricted stock units, restricted stock awards and performance stock awards (collectively, “Stock Awards”), stock options or any other stock-based award. As of March 27, 2020, approximately 17 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our stock-based compensation program refer to Note 17 of our 2019 Annual Report on Form 10-K. Stock-based Compensation Expense Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest. The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 Stock Awards: Pretax compensation expense $ 10.1 $ 7.8 Income tax benefit (1.9) (1.7) Stock Award expense, net of income taxes 8.2 6.1 Stock options: Pretax compensation expense 6.0 5.1 Income tax benefit (0.8) (1.1) Stock option expense, net of income taxes 5.2 4.0 Total stock-based compensation: Pretax compensation expense 16.1 12.9 Income tax benefit (2.7) (2.8) Total stock-based compensation expense, net of income taxes $ 13.4 $ 10.1 On February 20, 2020 the Board of Directors granted 2.3 million stock options and 0.8 million stock awards at market value to employees. The following summarizes the unrecognized compensation cost for the Stock Plan awards as of March 27, 2020. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions): Stock Awards $ 88.3 Stock options 115.9 Total unrecognized compensation cost $ 204.2 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 27, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 10. COMMITMENTS AND CONTINGENCIES For a description of our litigation and contingencies and additional information about our leases, refer to Note 16 and Note 10, respectively in our 2019 Annual Report on Form 10-K. Warranty We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a rollforward of our accrued warranty liability ($ in millions): Balance, December 31, 2019 $ 79.0 Accruals for warranties issued during the period 15.9 Settlements made (16.2) Effect of foreign currency translation (0.6) Balance, March 27, 2020 $ 78.1 Leases For the three months ended March 27, 2020 and March 29, 2019, operating lease cost was $21 million and $18 million, respectively. During the three-month periods ended March 27, 2020 and March 29, 2019, cash paid for operating leases included in operating cash flows was $19 million and $16 million, respectively. Right-of-use assets obtained in exchange for operating lease obligations were $7 million during the three months ended March 27, 2020 and immaterial during the three months ended March 29, 2019. As of March 27, 2020, we had entered into operating leases for which the lease had not yet commenced. These operating leases will commence in 2020 with lease terms between 2 and 15 years and have aggregate fixed payments of the non-cancelable lease terms of $23 million. |
Net Earnings Per Share
Net Earnings Per Share | 3 Months Ended |
Mar. 27, 2020 | |
Earnings Per Share [Abstract] | |
Net Earnings Per Share | NOTE 11. NET EARNINGS PER SHARE Basic net earnings per share (“EPS”) is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. There were 5.7 million anti-dilutive options excluded from the diluted EPS calculation for the three months ended March 27, 2020 and 1.7 million anti-dilutive options excluded from the diluted EPS calculation for the three months ended March 29, 2019. As described in Note 5, upon conversion of the Convertible Notes, holders will receive cash, shares of our common stock, or a combination thereof, at our election. Our intention is to settle such conversions through cash up to the principal amount of the Convertible Notes and, if applicable, through shares of our common stock for conversion value, if any, in excess of the principal amount of the Convertible Notes. We believe we have the ability to settle these obligations as intended, and therefore we have accounted for the conversion features under the treasury stock method in our calculation of EPS. Because the fair value of our common stock is below the conversion price, the Convertible Notes had no impact on our earnings per share for the three months ended March 27, 2020 and March 29, 2019. The impact of our Mandatory Convertible Preferred Stock (“MCPS”) calculated under the if-converted method was anti-dilutive for both the three month periods ended March 27, 2020 and March 29, 2019, and 18.4 million and 16.7 million shares were excluded from the diluted EPS calculation for each respective period. Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts): Three Months Ended March 27, 2020 March 29, 2019 Numerator Net earnings from continuing operations $ 42.3 $ 164.0 Mandatory convertible preferred stock cumulative dividends (17.3) (17.3) Net earnings attributable to common stockholders from continuing operations $ 25.0 $ 146.7 Denominator Weighted average common shares outstanding used in basic earnings per share 336.8 335.1 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive Stock Awards 3.2 4.4 Weighted average common shares outstanding used in diluted earnings per share 340.0 339.5 Net earnings from continuing operations per common share - Basic $ 0.07 $ 0.44 Net earnings from continuing operations per common share - Diluted $ 0.07 $ 0.43 We declared and paid cash dividends per common share for both periods as presented below. We declared and paid the MCPS dividend in the first quarter of 2019, while the MCPS dividend in the first quarter of 2020 was declared and accrued as follows: Dividend Per Amount Dividend per MCPS Amount 2020: First quarter $ 0.07 $ 23.5 $ 12.50 $ 17.3 2019: First quarter $ 0.07 $ 23.4 $ 12.50 $ 17.3 The first quarter 2020 MCPS dividends were paid on April 1, 2020. |
Segment Information
Segment Information | 3 Months Ended |
Mar. 27, 2020 | |
Segment Reporting [Abstract] | |
Segment Information | NOTE 12. SEGMENT INFORMATION We report our results in two separate business segments consisting of Professional Instrumentation and Industrial Technologies. When determining the reportable segments, we aggregated operating segments based on their similar economic and operating characteristics. Operating profit amounts in the Other category consist of unallocated corporate costs and other costs not considered part of our evaluation of reportable segment operating performance. Our segment results are as follows ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 Sales: (a) Professional Instrumentation $ 1,104.4 $ 977.7 Industrial Technologies 609.1 615.2 Total $ 1,713.5 $ 1,592.9 Operating Profit: (a) Professional Instrumentation $ 144.5 $ 142.7 Industrial Technologies (1.5) 98.8 Other (23.4) (24.2) Total Operating Profit 119.6 217.3 Interest expense, net (43.6) (25.3) Other non-operating expenses, net (4.6) 0.4 Earnings from continuing operations before income taxes $ 71.4 $ 192.4 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. |
Business Overview (Policies)
Business Overview (Policies) | 3 Months Ended |
Mar. 27, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Accumulated Other Comprehensive Income (Loss) | Accumulated Other Comprehensive Income (Loss) —Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. We have designated our Euro-denominated commercial paper and ¥13.8 billion senior unsecured term facility loan as net investment hedges of our investment in certain foreign operations. Accordingly, foreign currency transaction gains or losses on the debt are deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. We recognized gains of $0.9 million and $7.2 million for the three months ended March 27, 2020 and March 29, 2019, respectively, in other comprehensive income related to the net investment hedges. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three-month periods ended March 27, 2020 and March 29, 2019. |
Recently Issued Accounting Standards | Recently Adopted Accounting Standard —In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach, based on expected losses, to estimate credit losses on certain types of financial instruments, including financing, trade accounts, and unbilled receivables. On January 1, 2020, we adopted ASU 2016-13 and recognized in our Consolidated Condensed Balance Sheet as of January 1, 2020 an increase in the allowance for trade accounts, unbilled, and fi nancing receivables of $40.0 million, with a corresponding net of tax adjustment to beginning retained earnings of $31.3 million. Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Prior to the adoption of ASU 2016-13 on January 1, 2020, we recognized an allowance for incurred losses when they were probable based on many quantitative and qualitative factors, including delinquency. After the adoption of ASU 2016-13, we measure our allowance to reflect expected credit losses over the remaining contractual life of the asset. We pool assets with similar risk characteristics for this measurement based on attributes that may include asset type, duration, and/or credit risk rating. The future expected losses of each pool are estimated based on numerous quantitative and qualitative factors reflecting management’s estimate of collectibility over the remaining contractual life of the pooled assets, including: • duration; • historical, current, and forecasted future loss experience by asset type; • historical, current, and forecasted delinquency and write-off trends; • historical, current, and forecasted economic conditions; and • historical, current, and forecasted credit risk. Expected credit losses of the assets originated during the quarter ended March 27, 2020, as well as changes to expected losses during the same period, are recognized in earnings for the period ended March 27, 2020. As a result of the adoption of ASU 2016-13, we have updated our significant accounting policy related to unbilled, trade accounts, and financing receivables and allowances for credit losses as of March 27, 2020 from what was previously disclosed in our audited financial statements for the year ended December 31, 2019 as follows: All trade accounts, financing, and unbilled receivables are reported in the accompanying Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled, trade accounts, and financing receivable portfolios over the life of the underlying assets. Determination of the allowances requires management to exercise judgment about the severity of credit losses, which includes judgments regarding the risk profile of each underlying receivable and expectations regarding the impact of current and future economic conditions on the creditworthiness of its customers. We regularly perform detailed reviews of our portfolios to evaluate the collectability of receivables based on a combination of past, current, and future financial and qualitative factors that may affect customers’ ability to pay, including customers’ financial condition, collateral, debt-servicing ability, payment experience, credit bureau information, and economic conditions. In circumstances where we are aware of a specific customer’s inability to meet its financial obligations, a specific reserve is recorded against amounts due to reduce the recognized receivable to the amount reasonably expected to be collected. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. Recent deterioration in overall global economic conditions and worldwide capital markets as a result of the COVID-19 pandemic may negatively impact our customers’ ability to pay and, as a result, may increase the difficulty in collecting trade accounts, financing, and unbilled receivables. We did not realize notable increases in loss rates and delinquencies during the first quarter ended March 27, 2020, and given the nature of our portfolio of receivables, our historical experience during times of challenging economic conditions, and our forecasted future impact of COVID-19 on our customer’s ability to pay, we did not record material provisions for credit losses as a result of the COVID-19 pandemic during the first quarter ended March 27, 2020. If the financial condition of our customers were to deteriorate beyond our current estimates, resulting in an impairment of their ability to make payments, we would be required to write-off additional receivable balances, which would adversely impact our net earnings and financial condition. The following is a rollforward of the aggregated allowance for credit losses related to our trade accounts, unbilled, and financing receivables as of March 27, 2020 ($ in millions): Balance, December 31, 2019 $ 82.1 Transition Adjustment 40.0 Provision 12.0 Write-offs (13.2) FX and Other (5.1) Balance, March 27, 2020 $ 115.8 |
Sales | We derive revenues primarily from the sale of Professional Instrumentation and Industrial Technologies products and software and services. Revenue is recognized when control of promised products and software or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products and software or services. Sales of products and software includes revenues from the sale of products and equipment, software as a service product offerings, and equipment rentals. Sales of services includes revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, and services related to previously sold products. Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $76 million as of March 27, 2020 and $79 million as of December 31, 2019. Contract Costs — We incur direct incremental costs to obtain certain contracts, typically sales-related commissions and costs associated with assets used by our customers in certain service arrangements. Deferred sales-related commissions are generally not capitalized as the amortization period is one year or less, and we elected to use the practical expedient to expense these sales commissions as incurred. As of March 27, 2020 and December 31, 2019, we had $119 million and $147 million, respectively, in net revenue-related contract assets primarily related to certain software contracts. Revenue-related contract assets are recorded in the Prepaid expenses and other current assets and Other assets line items in our Condensed Consolidated Balance Sheets. These assets have estimated useful lives between 3 and 8 years. Impairment losses recognized on our revenue-related contract assets were immaterial during the three months ended March 27, 2020. Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to PCS and extended warranty sales, where in most cases we receive up-front payment and recognize revenue over the support term. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. |
Business Overview (Tables)
Business Overview (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Reclassification of Accumulated Other Comprehensive Income | The changes in AOCI by component are summarized below ($ in millions): Foreign Pension adjustments (b) Total For the Three Months Ended March 27, 2020: Balance, December 31, 2019 $ 21.2 $ (77.5) $ (56.3) Other comprehensive income (loss) before reclassifications, net of income taxes (136.3) — (136.3) Amounts reclassified from accumulated other comprehensive income (loss): Decrease — (1.2) (a) (1.2) Income tax impact — 0.2 0.2 Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — (1.0) (1.0) Net current period other comprehensive income (loss), net of income taxes (136.3) (1.0) (137.3) Balance, March 27, 2020 $ (115.1) $ (78.5) $ (193.6) For the Three Months Ended March 29, 2019: Balance, December 31, 2018 $ (29.3) $ (57.3) $ (86.6) Other comprehensive income (loss) before reclassifications, net of income taxes 16.7 — 16.7 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 0.7 (a) 0.7 Income tax impact — (0.2) (0.2) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.5 0.5 Net current period other comprehensive income (loss), net of income taxes 16.7 0.5 17.2 Balance, March 29, 2019 $ (12.6) $ (56.8) $ (69.4) (a) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 7 for additional details). (b) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans. |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | The following is a rollforward of the aggregated allowance for credit losses related to our trade accounts, unbilled, and financing receivables as of March 27, 2020 ($ in millions): Balance, December 31, 2019 $ 82.1 Transition Adjustment 40.0 Provision 12.0 Write-offs (13.2) FX and Other (5.1) Balance, March 27, 2020 $ 115.8 |
Acquisitions Acquisitions (Tabl
Acquisitions Acquisitions (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Business Combinations [Abstract] | |
Schedule of Business Acquisitions | The following table summarizes the provisional fair value estimates of the assets acquired and liabilities assumed of Principal and Non-Principal Countries that have been transferred to ASP as of March 27, 2020, prior to foreign currency impacts; we did not acquire accounts receivable or accounts payable from Johnson & Johnson: Advanced Sterilization Products Inventories $ 176.4 Property, plant and equipment 47.5 Goodwill 1,437.2 Other intangible assets, primarily customer relationships, trade names and technology 1,123.5 Other assets and liabilities, net (79.7) Total consideration allocated to Principal Countries and closed Non-Principal Countries 2,704.9 Prepaid acquisition asset related to remaining Non-Principal Countries 31.1 Net cash consideration $ 2,736.0 |
Goodwill (Tables)
Goodwill (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following is a rollforward of our carrying value of goodwill by segment ($ in millions): Professional Instrumentation (a) Industrial Technologies (a) Total Goodwill Balance, December 31, 2019 $ 7,242.6 $ 1,156.7 $ 8,399.3 Acquisitions 13.2 — 13.2 Impairment charge — (85.3) (85.3) Foreign currency translation and other (26.9) (29.2) (56.1) Balance, March 27, 2020 $ 7,228.9 $ 1,042.2 $ 8,271.1 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Liabilities Measured on Recurring Basis | Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions): Quoted Prices Significant Other Significant Total March 27, 2020 Deferred compensation liabilities $ — $ 27.3 $ — $ 27.3 December 31, 2019 Deferred compensation liabilities $ — $ 29.6 $ — $ 29.6 |
Carrying Amounts and Fair Values of Financial Instruments | The carrying amount and fair value of financial instruments are as follows ($ in millions): March 27, 2020 December 31, 2019 Carrying Amount Fair Value Carrying Amount Fair Value Current portion of long-term debt $ 250.0 $ 250.0 $ 1,500.0 $ 1,500.0 Long-term debt, net of current maturities $ 5,826.1 $ 5,755.9 $ 4,828.4 $ 4,992.3 |
Financing and Capital (Tables)
Financing and Capital (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The carrying value of the components of our long-term debt were as follows ($ in millions): March 27, 2020 December 31, 2019 U.S. dollar-denominated commercial paper $ 501.2 $ 884.4 Euro-denominated commercial paper 262.4 264.1 Delayed-draw term loan due 2020 1,000.0 1,000.0 Term Loan due 2020 250.0 500.0 Term Loan due 2021 373.9 — Yen variable interest rate term loan due 2022 127.8 127.1 2.35% senior unsecured notes due 2021 748.6 748.2 3.15% senior unsecured notes due 2026 893.3 893.0 4.30% senior unsecured notes due 2046 547.0 547.0 0.875% senior convertible notes due 2022 1,357.7 1,347.3 Other 14.2 17.3 Long-term debt 6,076.1 6,328.4 Less: current portion of long-term debt 250.0 1,500.0 Long-term debt, net of current maturities $ 5,826.1 $ 4,828.4 The details of our Commercial Paper Programs as of March 27, 2020 are as follows ($ in millions): Carrying value Annual effective rate Weighted average remaining maturity (in days) U.S. dollar-denominated commercial paper $ 501.2 2.67 % 37 Euro-denominated commercial paper $ 262.4 (0.11) % 34 |
Sales (Tables)
Sales (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Contract liabilities | Our contract liabilities consisted of the following ($ in millions): March 27, 2020 December 31, 2019 Deferred revenue - current $ 423.5 $ 410.1 Deferred revenue - noncurrent 95.1 99.2 Total contract liabilities $ 518.6 $ 509.3 |
Remaining performance obligations | The aggregate performance obligations attributable to each of our segments is as follows ($ in millions): March 27, 2020 Professional Instrumentation $ 145.2 Industrial Technologies 379.4 Total remaining performance obligations $ 524.6 |
Disaggregation of revenue | Disaggregation of revenue for the three months ended March 27, 2020 is presented as follows ($ in millions): Total Professional Instrumentation Industrial Technologies Sales: Sales of products and software $ 1,487.8 $ 940.5 $ 547.3 Sales of services 225.7 163.9 61.8 Total $ 1,713.5 $ 1,104.4 $ 609.1 Geographic: United States $ 1,019.8 $ 594.9 $ 424.9 China 127.5 119.0 8.5 All other (each country individually less than 5% of total sales) 566.2 390.5 175.7 Total $ 1,713.5 $ 1,104.4 $ 609.1 Major Products Group: Professional tools and equipment $ 1,107.3 $ 658.6 $ 448.7 Industrial automation, controls and sensors 109.6 109.6 — Franchise distribution 160.4 — 160.4 Medical technologies 280.0 280.0 — All other 56.2 56.2 — Total $ 1,713.5 $ 1,104.4 $ 609.1 End markets: Direct sales: Retail fueling (a) $ 396.5 $ — $ 396.5 Industrial & Manufacturing 109.0 109.0 — Vehicle repair (a) 143.2 — 143.2 Utilities & Power 43.9 43.9 — Medical (a) 280.0 280.0 — Other 355.8 290.8 65.0 Total direct sales 1,328.4 723.7 604.7 Distributors (a) 385.1 380.7 4.4 Total $ 1,713.5 $ 1,104.4 $ 609.1 (a) Retail fueling, vehicle repair and medical include sales to these end markets made through third-party distributors. Total distributor sales for the three months ended March 27, 2020 was $739.0 million. Disaggregation of revenue for the three months ended March 29, 2019 is presented as follows ($ in millions): Total Professional Instrumentation (a) Industrial Technologies (a) Sales: Sales of products and software $ 1,405.1 $ 856.2 $ 548.9 Sales of services 187.8 121.5 66.3 Total $ 1,592.9 $ 977.7 $ 615.2 Geographic: United States $ 887.6 $ 496.1 $ 391.5 China 150.0 131.2 18.8 All other (each country individually less than 5% of total sales) 555.3 350.4 204.9 Total $ 1,592.9 $ 977.7 $ 615.2 Major Products Group: Professional tools and equipment $ 1,151.8 $ 705.6 $ 446.2 Industrial automation, controls and sensors 120.1 120.1 — Franchise distribution 169.0 — 169.0 Medical technologies (d) 99.0 99.0 — All other 53.0 53.0 — Total $ 1,592.9 $ 977.7 $ 615.2 End markets: Direct sales: Retail fueling (c) $ 388.2 $ — $ 388.2 Industrial & Manufacturing 109.6 109.6 — Vehicle repair (c) 153.8 — 153.8 Utilities & Power 49.6 49.6 — Medical (c) (b) 99.0 99.0 — Other 377.7 309.9 67.8 Total direct sales 1,177.9 568.1 609.8 Distributors (c) 415.0 409.6 5.4 Total $ 1,592.9 $ 977.7 $ 615.2 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. (b) Sales were previously disclosed in Other. (c) Retail fueling, vehicle repair and medical include sales to these end markets made through third-party distributors. Total distributor sales for the three months ended March 29, 2019 was $745.2 million. (d) Sales were previously disclosed in Professional tools and equipment, Industrial automation, controls and sensors, and All other. |
Pension Plans (Tables)
Pension Plans (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Retirement Benefits [Abstract] | |
Schedule of Net Periodic Pension Costs | The following sets forth the components of our net periodic costs associated with our noncontributory defined benefit pension plans ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 U.S. Pension Benefits: Interest cost $ 0.3 $ 0.4 Expected return on plan assets (0.3) (0.3) Amortization of net loss 0.1 — Net periodic pension cost $ 0.1 $ 0.1 Non-U.S. Pension Benefits: Service cost $ 1.1 $ 0.3 Interest cost 1.0 1.4 Expected return on plan assets (1.4) (1.4) Amortization of net loss 1.1 0.7 Amortization of prior service cost 0.1 — Net periodic pension cost $ 1.9 $ 1.0 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock-Based Compensation Costs | The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 Stock Awards: Pretax compensation expense $ 10.1 $ 7.8 Income tax benefit (1.9) (1.7) Stock Award expense, net of income taxes 8.2 6.1 Stock options: Pretax compensation expense 6.0 5.1 Income tax benefit (0.8) (1.1) Stock option expense, net of income taxes 5.2 4.0 Total stock-based compensation: Pretax compensation expense 16.1 12.9 Income tax benefit (2.7) (2.8) Total stock-based compensation expense, net of income taxes $ 13.4 $ 10.1 |
Schedule of Future Compensation | Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions): Stock Awards $ 88.3 Stock options 115.9 Total unrecognized compensation cost $ 204.2 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Accrued Warranty Liability | The following is a rollforward of our accrued warranty liability ($ in millions): Balance, December 31, 2019 $ 79.0 Accruals for warranties issued during the period 15.9 Settlements made (16.2) Effect of foreign currency translation (0.6) Balance, March 27, 2020 $ 78.1 |
Net Earnings Per Share (Tables)
Net Earnings Per Share (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share | Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts): Three Months Ended March 27, 2020 March 29, 2019 Numerator Net earnings from continuing operations $ 42.3 $ 164.0 Mandatory convertible preferred stock cumulative dividends (17.3) (17.3) Net earnings attributable to common stockholders from continuing operations $ 25.0 $ 146.7 Denominator Weighted average common shares outstanding used in basic earnings per share 336.8 335.1 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive Stock Awards 3.2 4.4 Weighted average common shares outstanding used in diluted earnings per share 340.0 339.5 Net earnings from continuing operations per common share - Basic $ 0.07 $ 0.44 Net earnings from continuing operations per common share - Diluted $ 0.07 $ 0.43 |
Dividends Declared | We declared and paid cash dividends per common share for both periods as presented below. We declared and paid the MCPS dividend in the first quarter of 2019, while the MCPS dividend in the first quarter of 2020 was declared and accrued as follows: Dividend Per Amount Dividend per MCPS Amount 2020: First quarter $ 0.07 $ 23.5 $ 12.50 $ 17.3 2019: First quarter $ 0.07 $ 23.4 $ 12.50 $ 17.3 |
Segment Information (Tables)
Segment Information (Tables) | 3 Months Ended |
Mar. 27, 2020 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information | Our segment results are as follows ($ in millions): Three Months Ended March 27, 2020 March 29, 2019 Sales: (a) Professional Instrumentation $ 1,104.4 $ 977.7 Industrial Technologies 609.1 615.2 Total $ 1,713.5 $ 1,592.9 Operating Profit: (a) Professional Instrumentation $ 144.5 $ 142.7 Industrial Technologies (1.5) 98.8 Other (23.4) (24.2) Total Operating Profit 119.6 217.3 Interest expense, net (43.6) (25.3) Other non-operating expenses, net (4.6) 0.4 Earnings from continuing operations before income taxes $ 71.4 $ 192.4 (a) Beginning January 1, 2020, our Hengstler and Dynapar businesses are reported within our Professional Instrumentation segment. Previously, these businesses were reported within our Industrial Technologies segment. Prior year balances have been reclassified to reflect current year presentation. |
Business Overview - Narrative (
Business Overview - Narrative (Details) - USD ($) $ in Millions | Mar. 27, 2020 | Jan. 01, 2020 | Dec. 31, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Allowance for accounts, unbilled and financing receivables | $ 115.8 | $ 82.1 | |
Retained Earnings | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Adoption of accounting standard | $ (31.3) | ||
Accounting Standards Update 2016-13 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Allowance for accounts, unbilled and financing receivables | $ 40 |
Business Overview - Accumulated
Business Overview - Accumulated Other Comprehensive Income (Details) $ in Millions | 3 Months Ended | ||
Mar. 27, 2020USD ($) | Mar. 29, 2019USD ($) | Mar. 27, 2020JPY (¥) | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
(Loss) gain in OCI related to net investment hedge | $ 0.9 | $ 7.2 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | 7,400.2 | ||
Other comprehensive income (loss) before reclassifications, net of income taxes | (136.3) | 16.7 | |
Amounts reclassified from accumulated other comprehensive income (loss): | |||
Increase (Decrease) | (1.2) | 0.7 | |
Income tax impact | 0.2 | (0.2) | |
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | (1) | 0.5 | |
Total other comprehensive income (loss), net of income taxes | (137.3) | 17.2 | |
Ending balance | 7,253.3 | ||
Foreign currency translation adjustments | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | 21.2 | (29.3) | |
Other comprehensive income (loss) before reclassifications, net of income taxes | (136.3) | 16.7 | |
Amounts reclassified from accumulated other comprehensive income (loss): | |||
Increase (Decrease) | 0 | 0 | |
Income tax impact | 0 | 0 | |
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | 0 | 0 | |
Total other comprehensive income (loss), net of income taxes | (136.3) | 16.7 | |
Ending balance | (115.1) | (12.6) | |
Pension adjustments | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | (77.5) | (57.3) | |
Other comprehensive income (loss) before reclassifications, net of income taxes | 0 | 0 | |
Amounts reclassified from accumulated other comprehensive income (loss): | |||
Increase (Decrease) | (1.2) | 0.7 | |
Income tax impact | 0.2 | (0.2) | |
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | (1) | 0.5 | |
Total other comprehensive income (loss), net of income taxes | (1) | 0.5 | |
Ending balance | (78.5) | (56.8) | |
Accumulated Other Comprehensive Income (Loss) | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | (56.3) | (86.6) | |
Amounts reclassified from accumulated other comprehensive income (loss): | |||
Total other comprehensive income (loss), net of income taxes | (137.3) | 17.2 | |
Ending balance | $ (193.6) | $ (69.4) | |
Yen variable interest rate term loan due 2022 | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Term loan facility, aggregate amount | ¥ | ¥ 13,800,000,000 |
Business Overview - Allowance f
Business Overview - Allowance for Credit Losses Rollforward (Details) $ in Millions | 3 Months Ended |
Mar. 27, 2020USD ($) | |
Accounts And Financing Receivable, Allowance For Credit Loss [Roll Forward] | |
Beginning balance | $ 82.1 |
Provision | 12 |
Write-offs | (13.2) |
FX and Other | (5.1) |
Ending balance | 115.8 |
Cumulative Effect, Period of Adoption, Adjustment | |
Accounts And Financing Receivable, Allowance For Credit Loss [Roll Forward] | |
Beginning balance | $ 40 |
Acquisitions - Narrative (Detai
Acquisitions - Narrative (Details) $ in Millions | Apr. 01, 2019USD ($)country | Mar. 27, 2020USD ($)country | Dec. 31, 2018USD ($) |
Business Acquisition [Line Items] | |||
Acquisitions | $ 13.2 | ||
Prepaid acquisition asset related to remaining Non-Principal Countries | 31.1 | ||
Acquisitions, ASP | |||
Business Acquisition [Line Items] | |||
Net cash consideration | $ 2,700 | $ 2,736 | |
Revenue attributable to acquisition | $ 800 | ||
Number of principal countries | country | 20 | ||
Number of non-principal countries | country | 39 | ||
Number of principal countries, closed | country | 20 | ||
Number of non-principal countries, closed | country | 6 | ||
Percent of preliminary valuation in principal countries | 99.00% | ||
Percent of preliminary valuation in non-principal countries | 1.00% | ||
Prepaid acquisition asset related to remaining Non-Principal Countries | $ 31.1 | ||
Revenue since date of acquisition | 159 | ||
Operating loss since date of acquisition | 26 | ||
Amortization of intangible assets, acquisition-related fair value adjustments, and transaction costs | 52 | ||
Transaction-related costs | $ 20 |
Acquisitions - Advanced Sterili
Acquisitions - Advanced Sterilization Products Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions | Apr. 01, 2019 | Mar. 27, 2020 | Dec. 31, 2019 |
Business Acquisition [Line Items] | |||
Goodwill | $ 8,271.1 | $ 8,399.3 | |
Prepaid acquisition asset related to remaining Non-Principal Countries | 31.1 | ||
Acquisitions, ASP | |||
Business Acquisition [Line Items] | |||
Inventories | 176.4 | ||
Property, plant and equipment | 47.5 | ||
Goodwill | 1,437.2 | ||
Other intangible assets, primarily customer relationships, trade names and technology | 1,123.5 | ||
Other assets and liabilities, net | (79.7) | ||
Total consideration allocated to Principal Countries and closed Non-Principal Countries | 2,704.9 | ||
Prepaid acquisition asset related to remaining Non-Principal Countries | 31.1 | ||
Net cash consideration | $ 2,700 | $ 2,736 |
Goodwill - Rollforward of Goodw
Goodwill - Rollforward of Goodwill (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Goodwill [Roll Forward] | ||
Beginning balance | $ 8,399.3 | |
Acquisitions | 13.2 | |
Impairment of goodwill | (85.3) | $ 0 |
Foreign currency translation and other | (56.1) | |
Ending balance | 8,271.1 | |
Professional Instrumentation | ||
Goodwill [Roll Forward] | ||
Beginning balance | 7,242.6 | |
Acquisitions | 13.2 | |
Impairment of goodwill | 0 | |
Foreign currency translation and other | (26.9) | |
Ending balance | 7,228.9 | |
Industrial Technologies | ||
Goodwill [Roll Forward] | ||
Beginning balance | 1,156.7 | |
Acquisitions | 0 | |
Impairment of goodwill | (85.3) | |
Foreign currency translation and other | (29.2) | |
Ending balance | $ 1,042.2 |
Goodwill - Narrative (Details)
Goodwill - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 27, 2020 | Mar. 29, 2019 | Dec. 31, 2019 | |
Goodwill [Line Items] | |||
Impairment of goodwill | $ 85.3 | $ 0 | |
Goodwill | 8,271.1 | $ 8,399.3 | |
Telematics Reporting Unit | |||
Goodwill [Line Items] | |||
Reporting unit, percentage of fair value in excess of carrying amount | 5.00% | ||
Impairment of goodwill | 85.3 | ||
Goodwill | $ 235.9 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 27, 2020 | Mar. 29, 2019 | Dec. 31, 2019 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Current portion of long-term debt, carrying amount | $ 250 | $ 1,500 | |
Current portion of long-term debt, fair value | 250 | 1,500 | |
Long-term debt, net of current maturities, carrying value | 5,826.1 | 4,828.4 | |
Long-term debt, net of current maturities, fair value | 5,755.9 | 4,992.3 | |
Impairment of goodwill | 85.3 | $ 0 | |
Telematics Reporting Unit | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Impairment of goodwill | 85.3 | ||
Fair Value, Measurements, Recurring | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Deferred compensation liabilities | 27.3 | 29.6 | |
Fair Value, Measurements, Recurring | Quoted Prices in Active Market (Level 1) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Deferred compensation liabilities | 0 | 0 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Deferred compensation liabilities | 27.3 | 29.6 | |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Deferred compensation liabilities | $ 0 | $ 0 |
Financing and Capital - Compone
Financing and Capital - Components of Debt (Details) - USD ($) $ in Millions | Mar. 27, 2020 | Dec. 31, 2019 | Feb. 22, 2019 |
Debt Instrument [Line Items] | |||
Long-term debt | $ 6,076.1 | $ 6,328.4 | |
Current portion of long-term debt | 250 | 1,500 | |
Long-term debt, net of current maturities | 5,826.1 | 4,828.4 | |
Other | |||
Debt Instrument [Line Items] | |||
Long-term debt | 14.2 | 17.3 | |
Commercial Paper | U.S. dollar-denominated commercial paper | |||
Debt Instrument [Line Items] | |||
Long-term debt | 501.2 | 884.4 | |
Commercial Paper | Euro-denominated commercial paper | |||
Debt Instrument [Line Items] | |||
Long-term debt | 262.4 | 264.1 | |
Senior Notes | 2.35% senior unsecured notes due 2021 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 748.6 | 748.2 | |
Interest rate, stated percentage | 2.35% | ||
Senior Notes | 3.15% senior unsecured notes due 2026 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 893.3 | 893 | |
Interest rate, stated percentage | 3.15% | ||
Senior Notes | 4.30% senior unsecured notes due 2046 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 547 | 547 | |
Interest rate, stated percentage | 4.30% | ||
Convertible Debt | 0.875% senior convertible notes due 2022 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 1,357.7 | 1,347.3 | |
Interest rate, stated percentage | 0.875% | 0.875% | |
Line of credit | Delayed-draw term loan due 2020 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 1,000 | 1,000 | |
Line of credit | Term Loan due 2020 | |||
Debt Instrument [Line Items] | |||
Long-term debt | 250 | 500 | |
Line of credit | Term Loan due 2021 | |||
Debt Instrument [Line Items] | |||
Long-term debt | 373.9 | 0 | |
Line of credit | Yen variable interest rate term loan due 2022 | |||
Debt Instrument [Line Items] | |||
Long-term debt | $ 127.8 | $ 127.1 |
Financing and Capital - Narrati
Financing and Capital - Narrative (Details) | Oct. 01, 2021 | Jul. 02, 2021 | Apr. 24, 2020 | Apr. 03, 2020USD ($) | Mar. 23, 2020USD ($) | Feb. 26, 2020USD ($) | Nov. 08, 2019USD ($) | Oct. 25, 2019USD ($) | Mar. 20, 2019USD ($) | Mar. 01, 2019USD ($) | Feb. 22, 2019USD ($)$ / shares | Feb. 19, 2019$ / shares | Apr. 30, 2020USD ($) | Mar. 27, 2020USD ($) | Mar. 29, 2019USD ($) | Apr. 02, 2021 | Dec. 31, 2021 | Dec. 31, 2021 | Apr. 23, 2020USD ($) | Dec. 31, 2019USD ($) |
Debt Instrument [Line Items] | ||||||||||||||||||||
Debt discounts, premiums and issuance costs | $ 93,000,000 | $ 102,000,000 | ||||||||||||||||||
Share closing price (in dollars per share) | $ / shares | $ 80.48 | |||||||||||||||||||
Payments of debt issuance costs | $ 1,000,000 | $ 24,000,000 | ||||||||||||||||||
Revolving Credit Facility | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Debt term | 5 years | |||||||||||||||||||
Senior unsecured revolving credit facility | $ 2,000,000,000 | |||||||||||||||||||
Outstanding borrowings | $ 0 | |||||||||||||||||||
Revolving Credit Facility | Base Rate | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.00% | |||||||||||||||||||
Revolving Credit Facility | Base Rate | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.175% | |||||||||||||||||||
Revolving Credit Facility | Eurodollar | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.805% | |||||||||||||||||||
Revolving Credit Facility | Eurodollar | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.175% | |||||||||||||||||||
Line of credit | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Required consolidated net leverage ratio | 3.5 | |||||||||||||||||||
Required consolidated net leverage ratio following material acquisition | 4 | |||||||||||||||||||
Maximum percentage of principal amount of secured indebtedness to consolidated net assets | 15.00% | |||||||||||||||||||
Line of credit | London Interbank Offered Rate (LIBOR) | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.00% | |||||||||||||||||||
Line of credit | Base Rate | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.00% | |||||||||||||||||||
Convertible Debt | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Interest expense | $ 13,400,000 | |||||||||||||||||||
U.S. dollar-denominated commercial paper | Commercial Paper | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Short-term debt, refinanced | $ 365,000,000 | |||||||||||||||||||
Debt term | 37 days | |||||||||||||||||||
U.S. dollar-denominated commercial paper | Commercial Paper | Subsequent Event | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Short-term debt, refinanced | $ 420,000,000 | |||||||||||||||||||
Term Loan due 2020 | Line of credit | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Senior unsecured revolving credit facility | $ 500,000,000 | $ 300,000,000 | ||||||||||||||||||
Outstanding borrowings | $ 250,000,000 | |||||||||||||||||||
Long-term debt | $ 500,000,000 | |||||||||||||||||||
Proceeds from line of credit | $ 300,000,000 | |||||||||||||||||||
Increase in line of credit facility | $ 200,000,000 | |||||||||||||||||||
Interest rate at the end of the period | 1.55% | |||||||||||||||||||
Payment of outstanding principal | $ 250,000,000 | |||||||||||||||||||
Term Loan due 2020 | Line of credit | London Interbank Offered Rate (LIBOR) | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.75% | |||||||||||||||||||
Delayed-draw term loan due 2020 | Line of credit | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Outstanding borrowings | $ 1,000,000,000 | |||||||||||||||||||
Long-term debt | $ 1,000,000,000 | $ 1,000,000,000 | ||||||||||||||||||
Proceeds from line of credit | $ 1,000,000,000 | |||||||||||||||||||
Interest rate at the end of the period | 1.52% | |||||||||||||||||||
Delayed-draw term loan due 2020 | Line of credit | London Interbank Offered Rate (LIBOR) | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.75% | |||||||||||||||||||
Delayed-draw term loan due 2020 | Line of credit | London Interbank Offered Rate (LIBOR) | Subsequent Event | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.55% | |||||||||||||||||||
Term Loan due 2021 | Line of credit | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Debt term | 364 days | |||||||||||||||||||
Senior unsecured revolving credit facility | $ 425,000,000 | |||||||||||||||||||
Outstanding borrowings | $ 375,000,000 | |||||||||||||||||||
Long-term debt | $ 750,000,000 | |||||||||||||||||||
Basis spread on variable interest rate | 1.55% | |||||||||||||||||||
Proceeds from line of credit | $ 375,000,000 | |||||||||||||||||||
Interest rate at the end of the period | 2.51% | |||||||||||||||||||
Payments of debt issuance costs | $ 2,000,000 | |||||||||||||||||||
Term Loan due 2021 | Line of credit | Subsequent Event | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Outstanding borrowings | $ 750,000,000 | |||||||||||||||||||
Proceeds from line of credit | 375,000,000 | |||||||||||||||||||
Increase in line of credit facility | $ 325,000,000 | |||||||||||||||||||
The Amendments | Revolving Credit Facility | Base Rate | Forecast | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.18% | |||||||||||||||||||
The Amendments | Revolving Credit Facility | Base Rate | Forecast | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.55% | |||||||||||||||||||
The Amendments | Revolving Credit Facility | Eurodollar | Forecast | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.18% | |||||||||||||||||||
The Amendments | Revolving Credit Facility | Eurodollar | Forecast | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.55% | |||||||||||||||||||
The Amendments | Line of credit | Forecast | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Required consolidated net leverage ratio | 4.25 | 4.5 | 4.75 | 3.75 | ||||||||||||||||
Maximum percentage of principal amount of secured indebtedness to consolidated net assets | 11.25% | |||||||||||||||||||
The Amendments | Line of credit | Subsequent Event | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Debt issuance costs | $ 6,500,000 | |||||||||||||||||||
The Amendments | Line of credit | London Interbank Offered Rate (LIBOR) | Forecast | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.25% | |||||||||||||||||||
The Amendments | Line of credit | Base Rate | Forecast | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.25% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Base Rate | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.00% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Base Rate | Forecast | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.55% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Base Rate | Forecast | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.80% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Eurodollar | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.75% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Eurodollar | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 0.975% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Eurodollar | Forecast | Minimum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.55% | |||||||||||||||||||
Delayed-Draw Term Loan Due 2020, Extended Tranche | Revolving Credit Facility | Eurodollar | Forecast | Maximum | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Basis spread on variable interest rate | 1.80% | |||||||||||||||||||
0.875% senior convertible notes due 2022 | Convertible Debt | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Debt issuance costs | $ 24,300,000 | |||||||||||||||||||
Proceeds from the issuance of convertible notes | $ 1,400,000,000 | |||||||||||||||||||
Interest rate, stated percentage | 0.875% | 0.875% | ||||||||||||||||||
Principal amount | $ 1,300,000,000 | |||||||||||||||||||
Conversion ratio | 0.009378 | |||||||||||||||||||
Initial conversion price (in dollars per share) | $ / shares | $ 106.64 | |||||||||||||||||||
Threshold percentage of stock price trigger | 32.50% | |||||||||||||||||||
Discount at issuance | $ 102,200,000 | |||||||||||||||||||
Effective interest rate | 3.38% | |||||||||||||||||||
Interest expense related to contractual coupon rate | $ 3,100,000 | |||||||||||||||||||
Amortization of debt issuance costs | 1,900,000 | |||||||||||||||||||
Unamortized discount | $ 102,200,000 | $ 65,700,000 | ||||||||||||||||||
Discount amortization period | 3 years | |||||||||||||||||||
Senior Unsecured Notes due 2022, Over-Allotment Option | Convertible Debt | ||||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||||
Principal amount | $ 187,500,000 |
Financing and Capital - Commerc
Financing and Capital - Commercial Paper (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | ||
Carrying value | $ 6,076.1 | $ 6,328.4 |
Commercial Paper | U.S. dollar-denominated commercial paper | ||
Debt Instrument [Line Items] | ||
Carrying value | $ 501.2 | 884.4 |
Annual effective rate | 2.67% | |
Weighted average remaining maturity (in days) | 37 days | |
Commercial Paper | Euro-denominated commercial paper | ||
Debt Instrument [Line Items] | ||
Carrying value | $ 262.4 | $ 264.1 |
Annual effective rate | (0.11%) | |
Weighted average remaining maturity (in days) | 34 days |
Sales - Contract Assets (Detail
Sales - Contract Assets (Details) - USD ($) $ in Millions | Mar. 27, 2020 | Dec. 31, 2019 |
Revenue from Contract with Customer [Abstract] | ||
Contract Assets | $ 76 | $ 79 |
Sales - Contract Costs (Details
Sales - Contract Costs (Details) - USD ($) $ in Millions | Mar. 27, 2020 | Dec. 31, 2019 |
Capitalized Contract Cost [Line Items] | ||
Net revenue-related contract assets | $ 119 | $ 147 |
Maximum | ||
Capitalized Contract Cost [Line Items] | ||
Useful life | 8 years | |
Minimum | ||
Capitalized Contract Cost [Line Items] | ||
Useful life | 3 years | |
Deferred Sales Commissions | Maximum | ||
Capitalized Contract Cost [Line Items] | ||
Useful life | 1 year |
Sales - Contract liabilities (D
Sales - Contract liabilities (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Dec. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | ||
Deferred revenue - current | $ 423.5 | $ 410.1 |
Deferred revenue - noncurrent | 95.1 | 99.2 |
Total contract liabilities | 518.6 | $ 509.3 |
Contract liabilities, revenue recognized | $ 126 |
Sales - Revenue, Remaining Perf
Sales - Revenue, Remaining Performance Obligation (Details) $ in Millions | Mar. 27, 2020USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligations | $ 524.6 |
Professional Instrumentation | Operating Segments | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligations | 145.2 |
Industrial Technologies | Operating Segments | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligations | $ 379.4 |
Sales - Remaining Performance O
Sales - Remaining Performance Obligation, Expected Timing (Details) | Mar. 27, 2020 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-28 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percentage | 40.00% |
Remaining performance obligation, expected timing | 2 years |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-03-28 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percentage | 70.00% |
Remaining performance obligation, expected timing | 3 years |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-28 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percentage | 100.00% |
Remaining performance obligation, expected timing | 4 years |
Sales - Disaggregation of Reven
Sales - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Disaggregation of Revenue [Line Items] | ||
Sales | $ 1,713.5 | $ 1,592.9 |
Retail fueling | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 396.5 | 388.2 |
Industrial & Manufacturing | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 109 | 109.6 |
Vehicle repair | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 143.2 | 153.8 |
Utilities & Power | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 43.9 | 49.6 |
Medical | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 280 | 99 |
Other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 355.8 | 377.7 |
Total direct sales | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 1,328.4 | 1,177.9 |
Distributors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 385.1 | 415 |
Total Distributors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 739 | 745.2 |
Products | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 1,487.8 | 1,405.1 |
Services | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 225.7 | 187.8 |
Professional tools and equipment | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 1,107.3 | 1,151.8 |
Industrial automation, controls and sensors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 109.6 | 120.1 |
Franchise distribution | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 160.4 | 169 |
Medical technologies | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 280 | 99 |
All other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 56.2 | 53 |
Professional Instrumentation | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 1,104.4 | 977.7 |
Professional Instrumentation | Operating Segments | Retail fueling | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Professional Instrumentation | Operating Segments | Industrial & Manufacturing | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 109 | 109.6 |
Professional Instrumentation | Operating Segments | Vehicle repair | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Professional Instrumentation | Operating Segments | Utilities & Power | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 43.9 | 49.6 |
Professional Instrumentation | Operating Segments | Medical | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 280 | 99 |
Professional Instrumentation | Operating Segments | Other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 290.8 | 309.9 |
Professional Instrumentation | Operating Segments | Total direct sales | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 723.7 | 568.1 |
Professional Instrumentation | Operating Segments | Distributors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 380.7 | 409.6 |
Professional Instrumentation | Operating Segments | Products | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 940.5 | 856.2 |
Professional Instrumentation | Operating Segments | Services | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 163.9 | 121.5 |
Professional Instrumentation | Operating Segments | Professional tools and equipment | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 658.6 | 705.6 |
Professional Instrumentation | Operating Segments | Industrial automation, controls and sensors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 109.6 | 120.1 |
Professional Instrumentation | Operating Segments | Franchise distribution | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Professional Instrumentation | Operating Segments | Medical technologies | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 280 | 99 |
Professional Instrumentation | Operating Segments | All other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 56.2 | 53 |
Industrial Technologies | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 609.1 | 615.2 |
Industrial Technologies | Operating Segments | Retail fueling | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 396.5 | 388.2 |
Industrial Technologies | Operating Segments | Industrial & Manufacturing | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Industrial Technologies | Operating Segments | Vehicle repair | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 143.2 | 153.8 |
Industrial Technologies | Operating Segments | Utilities & Power | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Industrial Technologies | Operating Segments | Medical | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Industrial Technologies | Operating Segments | Other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 65 | 67.8 |
Industrial Technologies | Operating Segments | Total direct sales | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 604.7 | 609.8 |
Industrial Technologies | Operating Segments | Distributors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 4.4 | 5.4 |
Industrial Technologies | Operating Segments | Products | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 547.3 | 548.9 |
Industrial Technologies | Operating Segments | Services | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 61.8 | 66.3 |
Industrial Technologies | Operating Segments | Professional tools and equipment | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 448.7 | 446.2 |
Industrial Technologies | Operating Segments | Industrial automation, controls and sensors | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Industrial Technologies | Operating Segments | Franchise distribution | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 160.4 | 169 |
Industrial Technologies | Operating Segments | Medical technologies | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
Industrial Technologies | Operating Segments | All other | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 0 | 0 |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 1,019.8 | 887.6 |
United States | Professional Instrumentation | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 594.9 | 496.1 |
United States | Industrial Technologies | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 424.9 | 391.5 |
China | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 127.5 | 150 |
China | Professional Instrumentation | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 119 | 131.2 |
China | Industrial Technologies | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 8.5 | 18.8 |
All other (each country individually less than 5% of total sales) | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 566.2 | 555.3 |
All other (each country individually less than 5% of total sales) | Professional Instrumentation | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | 390.5 | 350.4 |
All other (each country individually less than 5% of total sales) | Industrial Technologies | Operating Segments | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 175.7 | $ 204.9 |
Pension Plans - Components of N
Pension Plans - Components of Net Periodic Pension Cost (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
United States | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Interest cost | $ 0.3 | $ 0.4 |
Expected return on plan assets | (0.3) | (0.3) |
Amortization of net loss | 0.1 | 0 |
Net periodic pension cost | 0.1 | 0.1 |
Non-U.S. | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Service cost | 1.1 | 0.3 |
Interest cost | 1 | 1.4 |
Expected return on plan assets | (1.4) | (1.4) |
Amortization of net loss | 1.1 | 0.7 |
Amortization of prior service cost | 0.1 | 0 |
Net periodic pension cost | $ 1.9 | $ 1 |
Pension Plans - Narrative (Deta
Pension Plans - Narrative (Details) $ in Millions | Mar. 27, 2020USD ($) |
Non-U.S. | |
Defined Benefit Plan Disclosure [Line Items] | |
Expected future contributions, remainder of fiscal year | $ 10.7 |
United States | |
Defined Benefit Plan Disclosure [Line Items] | |
Expected future contributions, remainder of fiscal year | $ 0.8 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 40.80% | 14.80% |
Stock-Based Compensation - Narr
Stock-Based Compensation - Narrative (Details) - shares shares in Millions | Feb. 20, 2020 | Mar. 27, 2020 |
Share-based Payment Arrangement [Abstract] | ||
Shares of common stock reserved for issuance under the Stock Plan (in shares) | 17 | |
Remaining service period related to the awards | 2 years | |
Number of options granted (shares) | 2.3 | |
Number of stock awards granted (shares) | 0.8 |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Pretax compensation expense | $ 16.1 | $ 12.9 |
Income tax benefit | (2.7) | (2.8) |
Total stock-based compensation expense | 13.4 | 10.1 |
Stock Awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Pretax compensation expense | 10.1 | 7.8 |
Income tax benefit | (1.9) | (1.7) |
Total stock-based compensation expense | 8.2 | 6.1 |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Pretax compensation expense | 6 | 5.1 |
Income tax benefit | (0.8) | (1.1) |
Total stock-based compensation expense | $ 5.2 | $ 4 |
Stock-Based Compensation - Unre
Stock-Based Compensation - Unrecognized Compensation Cost (Details) $ in Millions | Mar. 27, 2020USD ($) |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ 204.2 |
Stock Awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | 88.3 |
Stock options | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ 115.9 |
Commitments and Contingencies -
Commitments and Contingencies - Rollforward of Accrued Warranty Liability (Details) $ in Millions | 3 Months Ended |
Mar. 27, 2020USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |
Warranty period - minimum | 90 days |
Movement in Standard Product Warranty Accrual [Roll Forward] | |
Beginning balance | $ 79 |
Accruals for warranties issued during the period | 15.9 |
Settlements made | (16.2) |
Effect of foreign currency translation | (0.6) |
Ending balance | $ 78.1 |
Commitment and Contingencies -
Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Lessee, Lease, Description [Line Items] | ||
Operating lease cost | $ 21 | $ 18 |
Cash paid for operating leases | 19 | $ 16 |
ROU assets obtained in exchange for operating lease obligations | 7 | |
Operating lease, not yet commenced, liability | $ 23 | |
Maximum | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease, not yet commenced, term of contract | 15 years | |
Minimum | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease, not yet commenced, term of contract | 2 years |
Net Earnings Per Share - Narrat
Net Earnings Per Share - Narrative (Details) - shares shares in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 5.7 | 1.7 |
MCPS | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 18.4 | 16.7 |
Net Earnings Per Share - Earnin
Net Earnings Per Share - Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Numerator | ||
Net earnings from continuing operations | $ 42.3 | $ 164 |
Mandatory convertible preferred stock cumulative dividends | (17.3) | (17.3) |
Net earnings attributable to common stockholders from continuing operations | $ 25 | $ 146.7 |
Denominator | ||
Weighted average common shares outstanding used in basic earnings per share (in shares) | 336.8 | 335.1 |
Incremental common shares from: | ||
Assumed exercise of dilutive options and vesting of dilutive Stock Awards (in shares) | 3.2 | 4.4 |
Weighted average common shares outstanding used in diluted earnings per share (in shares) | 340 | 339.5 |
Net earnings per common share from continuing operations - basic (in dollars per share) | $ 0.07 | $ 0.44 |
Net earnings per common share from continuing operations - diluted (in dollars per share) | $ 0.07 | $ 0.43 |
Net Earnings Per Share - Divide
Net Earnings Per Share - Dividends Declared and Paid (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Earnings Per Share [Abstract] | ||
Dividend per Common Share (in dollars per share) | $ 0.07 | $ 0.07 |
Amount, Common Shares | $ 23.5 | $ 23.4 |
Dividend per share on MCPS (in dollars per share) | $ 12.50 | $ 12.50 |
Amount, MCPS | $ 17.3 | $ 17.3 |
Segment Information - Narrative
Segment Information - Narrative (Details) | 3 Months Ended |
Mar. 27, 2020segment | |
Segment Reporting [Abstract] | |
Number of operating segments | 2 |
Segment Information - Detailed
Segment Information - Detailed Segment Data (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 27, 2020 | Mar. 29, 2019 | |
Segment Reporting Information [Line Items] | ||
Sales | $ 1,713.5 | $ 1,592.9 |
Operating profit | 119.6 | 217.3 |
Interest expense, net | (43.6) | (25.3) |
Other non-operating expenses, net | (4.6) | 0.4 |
Earnings from continuing operations before income taxes | 71.4 | 192.4 |
Operating Segments | Professional Instrumentation | ||
Segment Reporting Information [Line Items] | ||
Sales | 1,104.4 | 977.7 |
Operating profit | 144.5 | 142.7 |
Operating Segments | Industrial Technologies | ||
Segment Reporting Information [Line Items] | ||
Sales | 609.1 | 615.2 |
Operating profit | (1.5) | 98.8 |
Other | ||
Segment Reporting Information [Line Items] | ||
Operating profit | $ (23.4) | $ (24.2) |
Uncategorized Items - ftv-20200
Label | Element | Value |
AOCI Attributable to Parent [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | $ (56,300,000) |
Common Stock [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 3,400,000 |
Noncontrolling Interest [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 13,200,000 |
Additional Paid-in Capital [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 3,311,100,000 |
Preferred Stock [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 0 |
Retained Earnings [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | $ 4,097,500,000 |